000168533 001__ 168533
000168533 005__ 20260211104147.0
000168533 0247_ $$2doi$$a10.1016/j.medcli.2025.107327
000168533 0248_ $$2sideral$$a147967
000168533 037__ $$aART-2026-147967
000168533 041__ $$aeng
000168533 100__ $$aCampos-Saenz de Santamaría, Amelia$$uUniversidad de Zaragoza
000168533 245__ $$aOutcome prediction in acute decompensated heart failure using the BAN-ADHF score across LVEF: Analysis in an internal medicine cohort
000168533 260__ $$c2026
000168533 5060_ $$aAccess copy available to the general public$$fUnrestricted
000168533 5203_ $$aBackground. The BAN-ADHF score integrates clinical, biomarker, and diuretic data to predict low diuretic efficiency and adverse events, offering a tool for individualized risk stratification. However, its performance in real-world settings remains understudied. No previous studies analyzed its usefulness across left ventricular ejection fraction (LVEF) phenotypes.
Methods. Observational and retrospective study carried out at the Internal Medicine Ward of a tertiary hospital between 2018 and 2024. Patients were classified into low (<12) and high-risk (≥12) groups. The primary endpoint was all-cause mortality and/or rehospitalization for heart failure (HF) at 180 days.
Results. A total of 472 patients were eligible. The mean age was 79.6 ± 9.4 years with 47.8% female and 64.6% of HF with preserved LVEF. Based on the BAN-ADHF score, 77.1% were categorized as “low-risk”, while 22.9% were classified as “high-risk”. High-risk patients were older (p = 0.019), more frequently male (p < 0.001), and had a higher comorbidity burden. At 180 days, the composite endpoint occurred in 30% of low-risk versus 64% of high-risk patients (p < 0.001). Mortality was 13.5% versus 41% (p < 0.001), and HF rehospitalization 42% versus 76% (p < 0.001). At one year, the combined outcome was 45% versus 76% (p < 0.001). High-risk status remained an independent predictor of adverse events (HR 2.8, 95% CI 2.1–3.8, p < 0.001). The BAN-ADHF score demonstrated acceptable predictive capacity (C-index 0.65).
Conclusions. The BAN-ADHF score reliably identifies high-risk patients with a significantly greater incidence of adverse events, independently including readmission, mortality, and their composite at 180 days in a real-world cohort regardless LVEF. Its integration into routine care may help guide early therapeutic strategies and resource allocation.
000168533 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B07-23R$$9info:eu-repo/grantAgreement/ES/DGA/T71-23D$$9info:eu-repo/grantAgreement/ES/MCIU/PID2022-139143OA-I00
000168533 540__ $$9info:eu-repo/semantics/embargoedAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000168533 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000168533 700__ $$aGodos-Gómez, Marc
000168533 700__ $$aCrespo-Aznarez, Silvia
000168533 700__ $$aEsterellas-Sánchez, Laura Karla
000168533 700__ $$0(orcid)0000-0002-2338-7637$$aSánchez-Marteles, Marta$$uUniversidad de Zaragoza
000168533 700__ $$aGarcés-Horna, Vanesa$$uUniversidad de Zaragoza
000168533 700__ $$0(orcid)0000-0002-6043-4869$$aGiménez-López, Ignacio$$uUniversidad de Zaragoza
000168533 700__ $$0(orcid)0000-0002-4769-7154$$aRubio-Gracia, Jorge$$uUniversidad de Zaragoza
000168533 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000168533 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000168533 773__ $$g166, 2 (2026), 107327$$pMed. clín.$$tMedicina clinica$$x0025-7753
000168533 8564_ $$s1363326$$uhttps://zaguan.unizar.es/record/168533/files/texto_completo.pdf$$yPostprint
000168533 8564_ $$s2176409$$uhttps://zaguan.unizar.es/record/168533/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000168533 909CO $$ooai:zaguan.unizar.es:168533$$particulos$$pdriver
000168533 951__ $$a2026-02-11-10:38:24
000168533 980__ $$aARTICLE